Kiyoshi Takayama on targeting challenging GPCRs using monoclonal antibodies

Kiyoshi Takayama has received a Ph.D. in pharmaceutical science
from the University of Tokyo. After his PhD he worked for more
than 12 years as a research scientist at Taisho Pharmaceutical,
Japan, where he was involved in the development of G-protein
coupled receptors (GPCRs) assay and the conducting of various
drug discovery programs for chronic inflammation and chronic
obstructive pulmonary disease (COPD). In 2006, Kiyoshi left
Taisho and founded NB Health Laboratory, a technology platform
company for the generation of functional mAbs targeting GPCRs. NB
Health Laboratory is pioneering a new field in GPCR-targeted drug
discovery by targeting GPCRs for lipid mediator ligands using
monoclonal antibodies.